Population Pharmacokinetic Analysis of Piperacillin/Tazobactam in Korean Patients with Acute Infections
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Yong Kyun | - |
dc.contributor.author | Jung, Jin Ah | - |
dc.contributor.author | Choi, Hyang-Ki | - |
dc.contributor.author | Bae, In-Gyu | - |
dc.contributor.author | Choi, Won Suk | - |
dc.contributor.author | Hur, Jian | - |
dc.contributor.author | Jin, Sung Joon | - |
dc.contributor.author | Kim, Shin-Woo | - |
dc.contributor.author | Kwon, Ki Tae | - |
dc.contributor.author | Lee, Sang-Rok | - |
dc.contributor.author | Shin, Jae-Gook | - |
dc.contributor.author | Kiem, Sungmin | - |
dc.date.accessioned | 2021-09-03T20:54:29Z | - |
dc.date.available | 2021-09-03T20:54:29Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2016-09 | - |
dc.identifier.issn | 2093-2340 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/87754 | - |
dc.description.abstract | Background: For more effective and safer usage of antibiotics, the dosing strategy should be individualized based on the patients' characteristics, including race. The aim of this study was to investigate the population pharmacokinetic (PK) profiles of piperacillin and tazobactam in Korean patients with acute infections. Materials and Methods: At least four consecutive 2/0.25 g or 4/0.5 g doses of piperacillin/tazobactam (TZP) were intravenously infused over 1 h every 8 h for patients with creatinine clearance (CLcr) <= 50 mL/min or CLcr >50 mL/min, respectively. Blood samples from 33 patients at a steady-state were taken pre-dose and at 0 min, 30 min, and 4-6 h after the fourth infusion. The population PK analysis was conducted using a non-linear mixed-effects method. A likelihood ratio test was used to select significant covariates, with significance levels of P < 0.05 for selection and P < 0.01 for elimination. Results: Both piperacillin PK and tazobactam PK were well described by a two-compartment model with first-order elimination. Creatinine clearance and body weight, as covariates on clearance (CL) and volume of central compartment (V1), were selected among the covariates possibly affecting PK parameters of both drugs. CL was defined as CL = 2.9 + 4.03 x CLcr/47 for piperacillin and CL = 1.76 + 4.81 x CLcr/47 for tazobactam. V1 was defined as V1 = 19.5 x weight/60 for piperacillin and V1 = 22.6 x weight/60 for tazobactam. Conclusion: The PK profiles of TZP at a steady-state in Korean patients with acute infections were well described by a two-compartment model with first-order elimination. Both piperacillin and tazobactam clearances were significantly influenced by creatinine clearance. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN SOC CHEMOTHERAPY | - |
dc.subject | MINIMUM INHIBITORY CONCENTRATION | - |
dc.subject | BETA-LACTAM ANTIBIOTICS | - |
dc.subject | PROLONGED INFUSION | - |
dc.subject | DRUG-THERAPY | - |
dc.subject | PHARMACODYNAMICS | - |
dc.subject | TAZOBACTAM | - |
dc.subject | PREDICTORS | - |
dc.subject | CHILDREN | - |
dc.subject | DOSAGE | - |
dc.subject | IMPACT | - |
dc.title | Population Pharmacokinetic Analysis of Piperacillin/Tazobactam in Korean Patients with Acute Infections | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Won Suk | - |
dc.identifier.doi | 10.3947/ic.2016.48.3.209 | - |
dc.identifier.wosid | 000390557600008 | - |
dc.identifier.bibliographicCitation | INFECTION AND CHEMOTHERAPY, v.48, no.3, pp.209 - 215 | - |
dc.relation.isPartOf | INFECTION AND CHEMOTHERAPY | - |
dc.citation.title | INFECTION AND CHEMOTHERAPY | - |
dc.citation.volume | 48 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 209 | - |
dc.citation.endPage | 215 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002153908 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Infectious Diseases | - |
dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
dc.subject.keywordPlus | MINIMUM INHIBITORY CONCENTRATION | - |
dc.subject.keywordPlus | BETA-LACTAM ANTIBIOTICS | - |
dc.subject.keywordPlus | PROLONGED INFUSION | - |
dc.subject.keywordPlus | DRUG-THERAPY | - |
dc.subject.keywordPlus | PHARMACODYNAMICS | - |
dc.subject.keywordPlus | TAZOBACTAM | - |
dc.subject.keywordPlus | PREDICTORS | - |
dc.subject.keywordPlus | CHILDREN | - |
dc.subject.keywordPlus | DOSAGE | - |
dc.subject.keywordPlus | IMPACT | - |
dc.subject.keywordAuthor | Piperacillin | - |
dc.subject.keywordAuthor | Tazobactam | - |
dc.subject.keywordAuthor | Race | - |
dc.subject.keywordAuthor | Population pharmacokinetics | - |
dc.subject.keywordAuthor | Clearance | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.